The announcement was made during market hours along with the company’s second-quarter earnings.
Dr. Lal has set November 7 as the record date for the interim dividend, while the record date for the bonus issue will be announced by the company later.
The company today reported a consolidated net profit of Rs 151 crore in the quarter ended September, up 17% from Rs 129 crore in the same period a year ago. Revenue from operations in the quarter under review was Rs 731 crore, up 11% from Rs 660 crore reported in Q2FY25.
Profit after tax (PAT) was 14% YoY on a sequential basis versus Rs 132 crore reported in Q1FY26, while revenue rose 9% from Rs 670 crore in the April-June quarter.
The stock traded positively in an otherwise weak market, rising 3.5% to touch the day’s high of Rs 3,194 around 2:30 pm. Dr. Lal’s earnings before interest, taxes, depreciation and amortization (EBITDA) in the reported quarter stood at Rs 224 crore, up 11% from Rs 202 crore in the year-ago period.
Management speaks
Commenting on the company’s performance, Executive Chairman Arvind Lal said he sees this decade as one of deep transformation. “The burden of chronic and lifestyle-related diseases continues to rise, requiring greater attention to early detection and continuous monitoring. As new therapies for diabetes, hypertension and obesity become more widely available, the role of diagnostics will only increase,” said Lal.
“Growing awareness around preventive healthcare, supported by rapid digital adoption, is helping millions of citizens get involved in organized healthcare for the first time. As the shift from unorganized to organized healthcare continues, we stand ready to responsibly take the lead and make meaningful contributions to India’s ambition of universal healthcare,” he added.
(Disclaimer: The recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of The Economic Times.)
#Lal #Path #Labs #announces #bonus #issue #declares #interim #dividend #7share